1. PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Surgical Robotics Combines Equipment Sales With Procedure Revenue
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) occupies the top position through its commercial surgical robotics business focused on urology. Its AQUABEAM and HYDROS systems deliver Aquablation therapy for benign prostatic hyperplasia, providing a defined medical application around which hospitals can build procedure programs.
Second-quarter 2026 revenue reached $94.5 million, up 19% year over year. U.S. procedure volume exceeded 13,100, an increase of approximately 21%, while U.S. handpiece and consumable revenue rose 12% to $48.4 million. Those figures illustrate the relationship between equipment placements and subsequent procedure-linked sales.
The financial picture still includes losses. Gross margin was 66%, but the quarterly net loss widened to $26.9 million as operating expenses increased. Cash, cash equivalents, and restricted cash totaled approximately $231 million.
The business also completed enrollment in its WATER IV prostate cancer study. That research offers a potential expansion opportunity, while remaining separate from its established BPH application.
Ranking Rationale
The No. 1 placement reflects an existing commercial platform, growing procedure volumes, and substantial consumable revenue. These provide measurable operating evidence for the investment thesis. Hospital purchasing decisions, continued adoption, and the path toward profitability remain the principal tests.
YOU MUST READ THIS: Top 6 Small-Cap Healthcare Stocks to Buy Right Now
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
